Get the Stockscreener App
2.70
1.50%
0.04
After Hours:
2.65
-0.05
-1.85%
Aadi Bioscience Inc Stock (AADI) Latest News
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Declines By 13.7% - MarketBeat
Aadi's Strategic Makeover: $100M FYARRO Exit Plus Game-Changing ADC Portfolio Acquisition - StockTitan
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Decrease in Short Interest - Defense World
Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - MarketBeat
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Growth in Short Interest - MarketBeat
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Increase in Short Interest - Defense World
ACUTA CAPITAL PARTNERS, LLC Expands Stake in Aadi Bioscience Inc - GuruFocus.com
Aadi Bioscience, Inc. (NASDAQ:AADI) Position Lowered by Jane Street Group LLC - Defense World
Aadi Bioscience, Inc. (NASDAQ:AADI) Shares Sold by Jane Street Group LLC - MarketBeat
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Rises By 136.0% - Defense World
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Grows By 136.0% - MarketBeat
Aadi Bioscience (NASDAQ:AADI) Shares Down 16.1% – What’s Next? - Defense World
Aadi Bioscience (NASDAQ:AADI) Trading Down 16.1%What's Next? - MarketBeat
Aadi Bioscience Enters Into Multiple Strategic Agreements, Including $100M Stock Purchase and License Agreement - Defense World
Aadi Bioscience, Inc. announced that it expects to receive $100.002392 million in funding from a group of investors - Marketscreener.com
Aadi Bioscience Sale of FYARRO® to Kaken Pharmaceutical and In-Licensing of Novel ADC Portfolio from WuXi Biologics - Leerink Partners
Aadi Bioscience Leads 3 Promising US Penny Stocks - Simply Wall St
Aadi Bioscience rockets 72% on key updates - MSN
Aadi Bioscience’s Strategic Agreements and Funding Moves - Yahoo Finance
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini
Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - Citeline
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Benzinga
Aadi Bioscience stock soars on licensing and sale deals - Investing.com India
Aadi Bioscience stock soars on licensing and sale deals By Investing.com - Investing.com UK
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - Marketscreener.com
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing - Yahoo Finance
Kaken Pharmaceutical Co., Ltd. agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - Marketscreener.com
Clinical Trials News Live Feed - StockTitan
AADI Enlists NY Court To Enforce Cancer Drug Award - Law360
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Decreases By 8.8% - MarketBeat
GSA Capital Partners LLP Cuts Stake in Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates - MSN
US Penny Stocks Under $90M Market Cap To Watch - Simply Wall St
BML Capital Management LLC Takes $4.12 Million Position in Aadi Bioscience, Inc. (NASDAQ:AADI) - MarketBeat
Aadi Bioscience Reports Q3 2024 Earnings and Growth - TipRanks
Aadi Bioscience Faces Potential Financial Strain from Securities Class Action Risks - TipRanks
Aadi Bioscience earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Aadi Bioscience Q3 Sales Surge 21% YoY, FYARRO Growth Drives Strong Performance | AADI Stock News - StockTitan
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update - PR Newswire
Aadi Bioscience to Report Third Quarter 2024 Results and Corpora - GuruFocus.com
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update - BioSpace
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Resu - GuruFocus.com
Aadi plunges 36% as phase 2 trial for solid tumors asset unlikely to meet goal - MSN
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):